Survival analyses and correlations with treatment and molecular features. (A) EFS and DFS probabilities within the complete cohort. (B) DFS probability of patients with PTLD-DLBCL treated with RIS and/or rituximab (R) and/or LDCT compared with that of cases treated with SOC-BNHL. (C) DFS probability of PTLD-DLBCL patients according to mutations affecting cell cycle signaling and (D) Notch pathway.